載入...

Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia

Dasatinib, a second-generation tyrosine kinase inhibitor, is used for treating patients with Philadelphia chromosome (Ph) positive leukemia, especially for those who are resistant or intolerant to imatinib. The common adverse effects associated to its use include myelosuppression, nausea, diarrhea,...

全面介紹

Na minha lista:
書目詳細資料
發表在:Onco Targets Ther
Main Authors: Chen, Runzhe, Wang, Fei, Zhang, Xiaoping, Gao, Chong, Chen, Baoan
格式: Artigo
語言:Inglês
出版: Dove Medical Press 2015
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4423504/
https://ncbi.nlm.nih.gov/pubmed/25960668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S83961
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!